Suven Life Sciences Limited (NSE:SUVEN)

India flag India · Delayed Price · Currency is INR
221.19
-12.43 (-5.32%)
Jun 6, 2025, 3:29 PM IST
153.37%
Market Cap 48.26B
Revenue (ttm) 75.74M
Net Income (ttm) -1.43B
Shares Out n/a
EPS (ttm) -6.58
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,475,325
Average Volume 2,063,236
Open 233.00
Previous Close 233.62
Day's Range 213.00 - 235.74
52-Week Range 88.05 - 250.48
Beta 0.82
RSI 60.53
Earnings Date May 28, 2025

About Suven Life Sciences

Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India, the United States, Europe, and internationally. The company engages in drug discovery and development of new chemical entities in central nervous system diseases. Its product candidates include Masupirdine (SUVN-502) for the treatment of Alzheimer disease and neuropsychiatric symptoms; Samelisant (SUVN-G3031), a histamine 3 recepto... [Read more]

Sector Healthcare
Founded 1989
Employees 141
Stock Exchange National Stock Exchange of India
Ticker Symbol SUVEN
Full Company Profile

Financial Performance

In 2023, Suven Life Sciences's revenue was 116.93 million, a decrease of -13.99% compared to the previous year's 135.95 million. Losses were -1.05 billion, -11.15% less than in 2022.

Financial Statements

News

Suven Life Sciences shares surge over 8% after clinical trial update

Shares of Suven Life Sciences Limited surged 8% on January 8, reaching ₹139.00 during the trading session. The sharp rise comes after the company announced the dosing of the first subjects in a Phase-...

5 months ago - Business Upturn

Suven Life Sciences initiates Phase-1 clinical trial for SUVN-I6107

Suven Life Sciences Limited has announced the dosing of the first subjects in a Phase-1 clinical trial for SUVN-I6107, a muscarinic M1 positive allosteric modulator (M1 PAM) aimed at treating cognitiv...

5 months ago - Business Upturn